Selecting patients for long-acting novel antipsychotic therapy

Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists
Tim Lambert

Abstract

As new psychopharmacological agents for the management of schizophrenia are introduced into clinical practice, inappropriate patient selection may often lead to disappointing outcomes for the patient, the family and services. Recently, the first and only long-acting novel antipsychotic was made available in Australia. Based on criteria used in a large clinical network in Victoria, this paper sets out to present six selection profiles for patients with schizophrenia who may be suitable candidates for treatment with this class of medication. Optimizing outcome for patients with enduring psychotic disorders involves enabling a stable psychopharmacological platform upon which to build a psychosocial therapies programme. Too often, problems with adherence undermine the recovery process. Long-acting novel antipsychotics ensure adherence, with all the advantages inherent in second-generation antipsychotics. Identifying patients a priori who might best respond to the long-acting novel antipsychotics may lead to improving the efficiency of the recovery process.

References

Apr 1, 1982·Clinical Pharmacology and Therapeutics·J F Dirks, R A Kinsman
May 1, 1994·Drugs·J M DavisL ] Metalon L [corrected to Matalon
Jun 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T R Barnes, D A Curson
Jan 1, 1997·The Psychiatric Quarterly·P Weiden, W Glazer
Jan 1, 1997·Schizophrenia Bulletin·W S FentonR K Heinssen
Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M KaneN R Schooler
May 9, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·J A Cramer, R Rosenheck
Oct 30, 1998·Journal of Psychiatric Research·B B Sheitman, J A Lieberman
May 4, 1999·Acta Psychiatrica Scandinavica. Supplementum·J Gerlach, E B Larsen
Mar 23, 2001·Acta Psychiatrica Scandinavica. Supplementum·M OehlW W Fleischhacker
May 2, 2003·The Medical Journal of Australia·Christos Pantelis, Timothy J R Lambert
Jun 5, 2003·The American Journal of Psychiatry·John M KaneKeith Karcher
Jan 28, 2004·The Journal of Clinical Psychiatry·Samuel J KeithHenry A Nasrallah
Mar 25, 2004·The Australian and New Zealand Journal of Psychiatry·Verity HumberstoneTim Lambert
Jul 21, 2004·Psychiatry Research·Hideki NakanoJun Nakamura
Aug 27, 2004·Schizophrenia Research·Matcheri S KeshavanNina Schooler
Nov 4, 2004·The Annals of Pharmacotherapy·Megan J Ehret, Matthew A Fuller
Apr 7, 2005·International Clinical Psychopharmacology·Hans-Jürgen MöllerUNKNOWN StoRMi Study Group
Apr 20, 2005·PharmacoEconomics·Natalie C EdwardsRonald J Diamond
Jun 13, 2012·The Australian and New Zealand Journal of Psychiatry·Anna WaterreusSonal Shah

❮ Previous
Next ❯

Citations

Oct 12, 2014·International Journal of Pharmaceutics·Amelia M Avachat, Sayali S Kapure

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
H E Lehmann, T A Ban
Acta psiquiátrica y psicológica de América latina
A J Lagomarsino
The Psychiatric Clinics of North America
Anthony F LehmanJulie Kreyenbuhl
© 2022 Meta ULC. All rights reserved